Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecfidera and Plegridy in Pediatric RRMS
NCT03870763Phase 3Terminated
- Sponsor
- Biogen
- Start
- Mar 2019
- Primary completion
- Jul 2022
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Dimethyl Fumarate, Peginterferon Beta-1a and Placebo (3 arms). Primary endpoint: Time to First Relapse at Week 96. Started Mar 2019; status: terminated.
02
Drugs
dimethyl fumaratepeginterferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03870763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870763.